Compare NNVC & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNVC | YI |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 30.8M |
| IPO Year | 2008 | 2018 |
| Metric | NNVC | YI |
|---|---|---|
| Price | $1.45 | $3.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 392.1K | 13.5K |
| Earning Date | 05-15-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $2.48 |
| 52 Week High | $2.23 | $11.17 |
| Indicator | NNVC | YI |
|---|---|---|
| Relative Strength Index (RSI) | 66.85 | 49.27 |
| Support Level | $1.45 | $3.49 |
| Resistance Level | $1.47 | $3.96 |
| Average True Range (ATR) | 0.09 | 0.29 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 96.71 | 71.79 |
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.